Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin Cream 1% vs Soolantra for Moderate to Severe Facial Rosacea
NCT04106726Phase 3Completed
- Sponsor
- Zydus Lifesciences Limited
- Start
- Oct 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivermectin in papulopustular rosacea (3 arms), sponsored by Zydus Lifesciences Limited. Primary endpoint: Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts. Started Oct 2019; status: completed.
02
Drugs
ivermectin
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT04106726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106726.